Flu/COVID/RSV fusion inhibitor

N/A

Report date: 2025/08/01 18:01:03
NME

Base Information

Drug NameFlu/COVID/RSV fusion inhibitor
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)
Mechanisms of ActionViral fusion inhibitor
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Syncytial Virus InfectionsInfluenza, Human
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDecoy Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDecoy Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Syncytial Virus InfectionsInfluenza, Human
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A